I don't really know. Hard to compare without clinical data.
At some point MRK could favour their own internal IDO and IDO-related drugs. I would think that *if* it gets to that, then the IDO class would have proven to be valuable.
On CALA's website, they note they've licensed things from Mars Corporation. I'm assuming this isn't Mars of Mars bars?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.